| Business Summary | | StemCells,
Inc.
is
a
biopharmaceutical
company
that
is
engaged
in
the
development
of
novel
stem
cell
therapies
designed
to
treat
and
possibly
cure,
human
diseases
and
disorders
such
as
Parkinson's
disease,
hepatitis,
diabetes
and
spinal
cord
injuries.
The
Company's
proposed
therapies
are
based
on
the
transplanting
of
healthy
human
stem
and
progenitor
cells
to
repair
or
replace
central
nervous
system,
pancreas
or
liver
tissue
that
has
been
damaged
or
lost
as
a
result
of
disease
or
injury.
The
Company
has
established
an
intellectual
property
position
in
all
three
areas
of
its
stem
cell
research,
the
central
nervous
system,
the
pancreas
and
the
liver,
by
patenting
its
discoveries
and
entering
into
exclusive
licensing
arrangements. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | StemCells,
Inc.
is
a
biotechnology
company
focused
on
the
discovery,
development
and
commercialization
of
stem
cell-based
therapies
to
treat
diseases
of
the
central
nervous
system,
liver
and
pancreas.
For
the
six
months
ended
6/30/01,
revenues
totalled
$400
thousand,
up
from
none.
Net
income
applicable
to
Common
totalled
$1.9
million,
vs.
a
loss
of
$2.6
million.
Results
reflect
initial
revenues
as
well
as
a
$7.8
million
gain
on
the
sale
of
the
Company's
investment
in
Modex. | More
from
Market Guide: Significant
Developments |
| | | | FY2000 Pay | |
| John Schwartz, Ph.D., 67 Chairman | -- | Martin McGlynn, 54 Pres,
CEO, Director | -- | Ronnda Bartel, Ph.D., 42 VP,
Scientific Devel. | $133K | Ann Tsukamoto, Ph.D., 48 VP,
Scientific Operations | 164K | Dollar amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|